COPD Treatment by Transplantation of Autologous Bronchial Basal Cells

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial

Official title:

Research on Chronic Obstructive Pulmonary Disease (COPD) Treatment by Transplantation of Autologous Bronchial Basal Cells

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05594303
• Other study ID #: 2018001
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 27, 2019
• Est. completion date: November 18, 2022

Study information

• Verified date: September 2023
• Source: Guangzhou Institute of Respiratory Disease
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Chronic obstructive pulmonary disease (COPD) is a group of disease characterized by obstructed airflow. Usually, the lung structure is gradually impaired along with the progression of the disease. Recently, the treatment of disease is challenged by shortage of approaches for regenerating the injured lung tissue. Here in this study, investigators intend to perform a single-centered, open, concurrent-controlled phase I/II clinical trial with autologous bronchial basal cells on COPD treatment since they were proved to regenerate lung tissue in animal models. The participants is recruited and divided into experiment group and control group. For patients from experiment group, bronchial basal cells will be isolated, expanded, carefully characterized in vitro and transplanted autologously into lung by fiberoptic bronchoscopy. No intervention is performed for patients from control group. During the study, the safety and efficacy will be evaluated on all the subjects by measuring the key indicators.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: November 18, 2022
• Est. primary completion date: May 16, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subjects aged between 40 to 75;

• Subjects diagnosed with COPD and meet the following standards: a. sustained airway obstruction; b. post-bronchodilator FEV1<80% predicted value;

• Subjects with DLCO<80% predicted value in spirometry;

• Subjects with a smoking history more than 10 pack-years (current smoker and former smoker);

• Subjects with stable condition for more than 4 weeks;

• Subjects tolerant to bronchoscopy;

• Subjects signed informed consent.

Exclusion Criteria:

• Pregnant or lactating women;

• Subjects with syphilis or any of HIV, HBV, HCV positive antibody;

• Subjects with any malignancy;

• Subjects requiring anti-infection (bacteria or virus) treatment by intravenous drugs;

• Subjects suffering from any of the following pulmonary diseases: asthma, active tuberculosis, pulmonary embolism, pneumothorax, pulmonary artery hypertension caused by other diseases;

• Subjects with a history of invasive or non-invasive mechanical ventilation in the past 4 weeks;

• Subjects suffering from other serious diseases, such as diabetes, myocardial infarction, unstable angina, cirrhosis, and acute glomerulonephritis;

• Subjects with leukopenia (WBC less than 4x10^9 / L) or agranulocytosis (WBC less than 1.5x10^9 / L or neutrophils less than 0.5x10^9 / L) caused by any reason;

• Subjects with severe renal impairment, serum creatinine> 1.5 times of the upper limit of normal;

• Subjects with liver disease or liver damage: ALT, AST, total bilirubin> 2 times of the upper limit of normal;

• Subjects with a history of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders;

• Subjects with severe arrhythmias (such as ventricular tachycardia, frequent superventricular tachycardia, atrial fibrillation, and atrial flutter, etc.) or cardiac degree II or above conduction abnormalities displayed via 12-lead ECG;

• Subjects with a history of alcohol or illicit drug abuse;

• Subjects allergic to products from cattle and pig;

• Subjects accepted by any other clinical trials within 3 months before the enrollment;

• Subjects with poor compliance, difficult to complete the study;

• Any other conditions that might increase the risk of subjects or interfere with the clinical trial.

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease (COPD)
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Biological:
• Autologuos transplantation of bronchial basal cells
Autologuos transplantation of bronchial basal cells

Locations

Country	Name	City	State
China	Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University	Guangzhou	Guangdong

Sponsors (2)

Lead Sponsor	Collaborator
Guangzhou Institute of Respiratory Disease	Regend Therapeutics

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diffusing capacity of the lung for carbon monoxide (DLCO)	It indicates the extent to which oxygen passes from the air sacs of the lungs into the blood	Change from baseline DLCO at 3 months after transplantation
Secondary	Forced expiratory volume in one second (FEV1)	It indicates the volume of air that can forcibly be blown out in first second, after full inspiration.	Before transplantation, 3 months after transplantation, 6 months after transplantation and a year after transplantation
Secondary	Forced vital capacity (FVC)	It indicates the volume of air that can forcibly be blown out after full inspiration.	Before transplantation, 3 months after transplantation, 6 months after transplantation and a year after transplantation
Secondary	The ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC)	It represents the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration to the full vital capacity	Before transplantation, 3 months after transplantation, 6 months after transplantation and a year after transplantation
Secondary	Maximum voluntary ventilation (MVV)	It indicates the maximum amount of air that can be inhaled and exhaled within one minute	Before transplantation, 3 months after transplantation, 6 months after transplantation and a year after transplantation
Secondary	6-minute-walk test (6MWT)	An indicator to evaluate the exercise function of patients with moderate or severe pulmonary heart diseases.	Before transplantation, 3 months after transplantation, 6 months after transplantation and a year after transplantation
Secondary	Imaging of lung structure by computed tomography (CT)	Images of lung will be analyzed to indicate the newly-derived pulmonary structure.	Before transplantation, 3 months after transplantation, 6 months after transplantation and a year after transplantation
Secondary	Assess life quality affected by the respiratory problem by St. George's respiratory questionnaire (SGRQ) scale	Quality of life was assessed by St. George's respiratory questionnaire (SGRQ) scale. Total score, ranged from 0 to 100, is the sum of points from all items. A higher value represents a worse outcome.	Before transplantation, 3 months after transplantation, 6 months after transplantation and a year after transplantation
Secondary	Chronic obstructive pulmonary disease assessment test (CAT)	A patient-completed questionnaire assessing all aspects of the impact of Chronic obstructive pulmonary disease. Higher scores represent a worse outcome.	Before transplantation, 3 months after transplantation, 6 months after transplantation and a year after transplantation
Secondary	Diffusing capacity of the lung for carbon monoxide (DLCO)	It indicates the extent to which oxygen passes from the air sacs of the lungs into the blood	Change from baseline DLCO at 6 months after transplantation
Secondary	Diffusing capacity of the lung for carbon monoxide (DLCO)	It indicates the extent to which oxygen passes from the air sacs of the lungs into the blood	Change from baseline DLCO at 12 months after transplantation